Page last updated: 2024-10-22

amiodarone and Anemia, Sickle Cell

amiodarone has been researched along with Anemia, Sickle Cell in 1 studies

Amiodarone: An antianginal and class III antiarrhythmic drug. It increases the duration of ventricular and atrial muscle action by inhibiting POTASSIUM CHANNELS and VOLTAGE-GATED SODIUM CHANNELS. There is a resulting decrease in heart rate and in vascular resistance.
amiodarone : A member of the class of 1-benzofurans that is 1-benzofuran substituted by a butyl group at position 2 and a 4-[2-(diethylamino)ethoxy]-3,5-diiodobenzoyl group at position 3. It is a cardiovascular drug used for the treatment of cardiac dysrhythmias.

Anemia, Sickle Cell: A disease characterized by chronic hemolytic anemia, episodic painful crises, and pathologic involvement of many organs. It is the clinical expression of homozygosity for hemoglobin S.

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's0 (0.00)24.3611
2020's1 (100.00)2.80

Authors

AuthorsStudies
Venugopal, J1
Wang, J1
Guo, C1
Eitzman, DT1

Other Studies

1 other study available for amiodarone and Anemia, Sickle Cell

ArticleYear
Amiodarone improves anemia in a murine model of sickle cell disease and is associated with increased erythrocyte bis(monoacylglycerol) phosphate.
    Scientific reports, 2022, 09-30, Volume: 12, Issue:1

    Topics: Amiodarone; Anemia, Sickle Cell; Animals; Antibodies, Neutralizing; Disease Models, Animal; Erythroc

2022